On February 10, 2025, COGI provided comments to the Virginia legislature highlighting our concerns about legislation to create a Prescription Drug Affordability Board, HB 1724, and its potential to entrench discrimination and increase utilization management strategies from payers that impact patient access to care. We are concerned that the legislation does not protect patients from adverse formulary placement of drugs, thereby entrenching existing health disparities when patients cannot get the drug that would be most effective. View the letter here.
